Phase 2 study of Tovorafenib (Day 101) in Relapsed and Refractory Langerhans Cell Histiocytosis Grant uri icon

Overview

date/time interval

  • November 1, 2025 - October 31, 2027

sponsor award ID

  • BMS 252199-01

Affiliation